Genetic variants in XRRC5 may predict development of venous thrombotic events in myeloma patients on thalidomide.
نویسندگان
چکیده
stem cell transplantation in children following reduced intensity conditioning: potential predictive value of NK cell chimaerism for late graft rejection. Leukemia. 2003;17:1934-1942. 7. Seidel MG, Ernst U, Printz D, et al. Expression of the putatively regulatory T-cell marker FOXP3 by CD4( )CD25 T cells after pediatric hematopoietic stem cell transplantation. Haematologica. 2006;91:566-569. 8. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4 CD25naive T cells to CD4 CD25 regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198:18751886. 9. Morgan ME, van Bilsen JH, Bakker AM, et al. Expression of FOXP3 mRNA is not confined to CD4 CD25 T regulatory cells in humans. Hum Immunol. 2005;66:13-20. 10. Walker MR, Carson BD, Nepom GT, Ziegler SF, Buckner JH. De novo generation of antigen-specific CD4 CD25 regulatory T cells from human CD4 CD25cells. Proc Natl Acad Sci U S A. 2005;102:41034108.
منابع مشابه
Thalidomide-associated arterial thrombosis: two case reports.
Introduction Thalidomide was used as a sedative in the 1950s and was withdrawn from the market after initial reports of teratogenicity in 1961. In 1998, the US Food and Drug Administration (FDA) approved the drug as a treatment for erythema nodosum leprosum. The finding of increased angiogenesis in myeloma, coupled with the recognition of the antiangiogenic properties of thalidomide, led to the...
متن کاملComplex Arterial and Venous Thrombosis in Polycythemia Vera: what Does Leukocytosis Predict?
Thromboembolic events represent the main cause of morbidity and mortality in patients with polycythemia vera. Leukocytosis has been identified as an important risk factor for development of vascular thrombosis. A 47-year-old woman with polycythemia vera presented with pain and swelling in her right calf. She was scheduled to receive anagrelide which was effective on polycythemia and thrombocyto...
متن کاملGenetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.
A venous thromboembolism (VTE) with the subsequent risk of pulmonary embolism is a major concern in the treatment of patients with multiple myeloma with thalidomide. The susceptibility to developing a VTE in response to thalidomide therapy is likely to be influenced by both genetic and environmental factors. To test genetic variation associated with treatment related VTE in patient peripheral b...
متن کاملMultifocal Arterial Thrombosis during Thalidomide Therapy: Case Report and Review of the Literature
Introduction. Thalidomide has been associated with both venous and arterial thrombotic events. Case Presentation. A 66-years old man during thalidomide therapy for myeloma experienced acute right arm ischemia, emergently treated with thrombectomy and, on postoperative day one left side weakness with right internal carotid thrombosis. Discussion. Because of the increased risk of arterial thrombo...
متن کاملThalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis
BACKGROUND Thalidomide is an immunomodulatory and anti-angiogenic drug that has shown promise in patients with myeloma. Trials comparing efficacy of standard melphalan and prednisone (MP) therapy with MP plus thalidomide (MPT) in transplant-ineligible or elderly patients with multiple myeloma (MM) have provided conflicting evidence. This meta-analysis aimed to determine the efficacy and toxicit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Blood
دوره 113 22 شماره
صفحات -
تاریخ انتشار 2009